Based on research presented at the 2018 National Comprehensive Cancer Network Annual Conference, patients weighing 60 kg to 85 kg who often receive lower-than-recommended doses of filgrastim, without evidence of its noninferiority to recommended doses, is found to be not only acceptable, but also cost-saving.
The American Society of Clinical Oncology and the National Comprehensive Cancer Network collaborated to jointly develop a new guideline to help clinicians recognize and manage the range of side effects from immune checkpoint inhibitors.
“There’s a human behind the patient, and he can tell us what he needs. He’s really the expert in the field,” Christine B. Boers-Doets, MSc, Netherlands Leiden University Medical Center, told attendees at the recent ESMO International Consensus Conference for Advanced Breast Cancer.
To sign up for our newsletter or print publications, please enter your contact information below.
Subscribe to recieve the free, monthly TON print publication and TON weekly e‑newsletter.